Drug Trial Radar · NCT04493424
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
108
Actual
Start
Sep 4, 2020
Primary completion
Jan 16, 2023
Study completion May 15, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab. Participants who benefited from spesolimab treatment in the previous studies can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with palmoplantar pustulosis in the long-term. Participants are in this study for up to 5 years. During this time they visit the study site every month to get spesolimab injections under the skin. At study visits, doctors check the severity of participants' palmoplantar pustulosis and collect information on any health problems of the participants.
Conditions
- Palmoplantar Pustulosis
Interventions
SpesolimabDrug
Spesolimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Treatment Emergent Adverse Events (TEAEs)Time frame: From first administration of study drug until last administration of study drug + 112 days, up to 869 days.
Locations
66 sites in 14 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama
University of Missouri Health System
Columbia, Missouri
The Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Menter Dermatology Research Institute
Dallas, Texas
University of Utah Health
Murray, Utah
Paratus Clinical Research Woden
Phillip, Australian Capital Territory, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Skin Health Institute Inc
Carlton, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Brussels - UNIV Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Dr. Irina Turchin PC Inc.
Fredericton, New Brunswick, Canada
SimcoDerm Medical and Surgical Dermatology Centre
Barrie, Ontario, Canada
The Guenther Dermatology Research Centre
London, Ontario, Canada
Innovaderm Research Inc.
Montreal, Quebec, Canada
CCBR Czech a.s.
Pardubice, Czechia
Univ. Hospital Kralovske Vinohrady
Prague, Czechia
Sanatorium Prof. Arenebergera
Prague, Czechia
HOP l'Archet
Nice, France
HOP Saint-Louis
Paris, France
HOP Larrey
Toulouse, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, Germany
University of Pecs
Pécs, Hungary
Markusovszky University Teaching Hospital
Szombathely, Hungary
Fujita Health University Hospital
Aichi, Toyoake, Japan
Tokyo Dental College Ichikawa General Hospital
Chiba, Ichikawa, Japan
Fukuoka University Hospital
Fukuoka, Fukuoka, Japan
Gifu University Hospital
Gifu, Gifu, Japan
Asahikawa Medical University Hospital
Hokkaido, Asahikawa, Japan
Takagi Dermatological Clinic
Hokkaido, Obihiro, Japan
Takamatsu Red Cross Hospital
Kagawa, Takamatsu, Japan
Sagamihara National Hospital
Kanagawa, Sagamihara, Japan
Kumamoto University Hospital
Kumamoto, Kumamoto, Japan
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, Japan
Tohoku University Hospital
Miyagi, Sendai, Japan
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.